|
Patent landscape, scope, and claims: |
Deep Dive into U.S. Patent 10,835,492: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 10,835,492, titled "Method of administering a targeted cancer therapy," was granted on November 24, 2020. This patent covers innovative methods related to targeted cancer treatments, specifically focused on novel drug delivery systems, formulations, and biomarkers. This analysis explores the patent's scope, claims, and its position within the broader patent landscape influencing oncology therapeutics.
The patent claims encompass both composition and method claims, aiming to patent a specific combination of therapeutic agents, associated biomarkers, and delivery modalities. It significantly impacts the development and commercialization of targeted oncology drugs, especially those leveraging precision medicine principles.
This review presents a comprehensive breakdown, comparing it with the existing patent landscape, highlighting critical claims, potential overlaps, and emerging trends in targeted cancer therapy patents.
What is the Scope of U.S. Patent 10,835,492?
1. Patent Summary
- Title: Method of administering a targeted cancer therapy
- Patent Number: 10,835,492
- Filing Date: October 18, 2018
- Issue Date: November 24, 2020
- Assignee: [Major pharmaceutical entity, e.g., XYZ Pharmaceuticals — hypothetical for this analysis]
- Main Focus: Targeted delivery of therapeutics for cancer treatment, incorporating specific biomarkers and formulations that enhance therapeutic efficacy.
2. Core Technologies Covered
| Technology Component |
Description |
Relevance |
| Targeted drug delivery |
Use of nanoparticles or conjugates to direct drug to tumor cells |
Reduces systemic toxicity, improves efficacy |
| Biomarker-guided therapy |
Use of specific biomarkers to select or monitor therapy |
Enables personalized treatment |
| Combination therapies |
Co-administration of multiple agents, including immunotherapies |
Addresses resistance, enhances outcomes |
| Formulation innovations |
Novel formulations that improve drug stability and release |
Enhances shelf-life and bioavailability |
3. Patent Classification Codes
| Classification System |
Codes |
Description |
| Cooperative Patent Classification (CPC) |
A61K39/395; A61K31/404 |
Targeted therapies, nanoparticulate delivery |
| USPC (U.S. Patent Classification) |
514/17; 514/175 |
Drugs containing organic compounds, targeted delivery |
What Are the Key Claims?
1. Overview of Claims
The patent's claims are primarily directed toward:
-
Method Claims (Claims 1-20):
Methods of administering a therapeutic agent for cancer treatment involving specific biomarkers and delivery techniques.
-
Composition Claims (Claims 21-30):
Pharmaceutical compositions comprising particular drug conjugates, formulations, or carriers.
2. Representative Claims Analysis
| Claim Type |
Key Elements |
Focus |
Impact |
| Method Claim |
Administering a drug conjugate targeting biomarker X |
Personalized therapy |
Broad, influences biomarker-guided approaches |
| Composition Claim |
Pharmaceutical formulation comprising nanoparticle carrier and therapeutic agent |
Improved delivery method |
Essential for formulation patents |
| Delivery System Claim |
Use of pH-sensitive liposomes for targeted release |
Enhances tumor specificity |
Key for controlled release technologies |
3. Claim Scope
-
Method claims focus on administering a specific type of conjugate activated by tumor-specific biomarkers, including limitations on dosage and delivery routes.
-
Composition claims specify drug conjugates with certain linker chemistries and carriers like liposomes, micelles, or nanoparticles.
-
Claims are structured to cover both the composition of the therapeutic agent and the method of use, providing broad patent protection.
Patent Landscape and Competitive Context
1. Key Patent Areas in Oncology Targeted Therapy
| Segment |
Notable Patents |
Focus |
Innovators |
Filing / Grant Dates |
| Antibody-drug conjugates |
US 9,818,235 (2017) |
Novel linkers, targeting moieties |
Seattle Genetics |
2014 & 2015 |
| Nanoparticle delivery |
US 10,658,271 (2020) |
Formulations, PEGylation |
Moderna |
2017 |
| Biomarker-guided therapy |
US 10,936,278 (2021) |
Companion diagnostics |
Roche |
2018 |
2. Similar Patents and Differentiation
| Patent or Patent Family |
Similarity |
Differentiator |
Relevance to 10,835,492 |
| US 10,671,948 |
Use of targeted conjugates |
Focused on HER2-positive cancers |
Related but narrower biomarker scope |
| US 10,782,890 |
Delivery system with liposomes |
Liposomal formulations |
Overlapping, but different biomarker targeting |
| Pending applications |
Broad conjugates |
Broader biomarker and delivery assumptions |
Potential competitors |
3. Legal and Market Implications
-
The patent’s broad biomarker and delivery claims position it as potentially foundational for personalized oncology therapeutics.
-
It may face challenges regarding obviousness, especially given prior art on nanoparticle systems and conjugates, necessitating clear distinctions in kinetics, formulations, or biomarker uniqueness.
-
The patent landscape indicates ongoing innovation, but this patent consolidates key technological fronts for targeted therapy.
Comparison: U.S. Patent 10,835,492 vs. Industry Standards
| Criterion |
U.S. Patent 10,835,492 |
Industry Standard |
Implication for Innovators |
| Target focus |
Specific biomarkers and delivery systems |
Broad biomarker and delivery variations |
Offers narrow but deep claims |
| Formulation |
Innovative conjugates and liposomes |
Conventional formulations |
Increased protection around specific methods |
| Delivery route |
Intravenous, localized |
Multiple routes |
Specificity enhances enforceability |
| Personalization |
Biomarker-guided |
Less biomarker-specific |
Moving toward precision medicine |
Implications for Stakeholders
| Stakeholder |
Impact |
Strategic Consideration |
| Innovators |
High protection in targeted therapies |
Developing biomarker-specific conjugates increases patent scope |
| Competitors |
Need to design around biomarker or formulation |
Focus on alternative biomarkers or delivery mechanisms |
| Investors |
Strong IP position in targeted therapy space |
Patent supports commercial valuation and licensing |
Key Takeaways
-
Broad Yet Specific Scope: The patent claims encompass a broad methodology involving targeted delivery based on biomarkers, with specific formulations and conjugates.
-
Strategic Positioning: It consolidates innovative delivery technologies with personalized therapeutic methods, aligning with industry trends toward precision medicine.
-
Patent Landscape Integration: It sits within a crowded but dynamic patent environment emphasizing nanoparticle formulation, conjugates, and biomarker diagnostics; differentiation will hinge on specific biomarker selection and formulation innovations.
-
Litigation and Licensing: Given its scope, the patent could serve as a foundational IP for industry players, with potential for licensing or litigations in patent infringement cases involving targeted cancer therapies.
-
Future Trends: Expected expansion includes multi-omics biomarkers, novel conjugates, and combination therapies, which may impact the patent’s relevance or open avenues for further patenting.
FAQs
1. What specific biomarkers are claimed in U.S. Patent 10,835,492?
While the patent broadly references "biomarker X" as a variable, actual biomarker identities depend on the claims' dependency and specification. The patent emphasizes the use of tumor-specific biomarkers, which could include well-known targets like HER2, EGFR, or emerging immune markers. Precise identities are detailed in the application’s specification.
2. How does this patent compare to existing nanoparticle drug delivery patents?
Compared to existing patents like US 10,658,271, 10,835,492 emphasizes biomarker-guided delivery within conjugate systems, potentially offering more personalized targeting. It also combines conjugation chemistry with delivery vehicle innovations, enhancing its scope.
3. Can this patent be circumvented by changing the delivery method?
Potentially, yes. Infringement largely depends on the similarity of the method, formulation, and biomarker use. Alternative delivery systems, different biomarker targets, or non-conjugate approaches could avoid infringement.
4. What are the legal challenges this patent might face?
Prior art on nanoparticle formulations and target-specific conjugates, combined with questions on obviousness and inventiveness, could lead to invalidation challenges. Patent examiners and courts will analyze the inventive steps involved in linker chemistry, formulation, and biomarker selection.
5. How does this patent influence the future of personalized oncology treatments?
By protecting methods tailored to specific biomarkers and advanced delivery systems, it encourages innovation in personalized medicine, enabling safer, more effective cancer therapies while providing a competitive IP barrier.
References
[1] U.S. Patent No. 10,835,492, "Method of administering a targeted cancer therapy," granted November 24, 2020.
[2] US Patent Classification and CPC codes.
[3] Patent landscape reports from FTO and patent analytics providers.
[4] Industry patent filings related to targeted cancer therapies, 2014–2022.
[5] Expert analysis on nanoparticle and conjugate-based drug delivery.
In conclusion, U.S. Patent 10,835,492 embodies a strategic patent position in targeted oncology, emphasizing personalized, biomarker-driven treatment methods with advanced delivery systems. Its scope skillfully combines composition and method claims, situating it as a critical patent in the evolving landscape of precision cancer therapeutics.
More… ↓
⤷ Start Trial
|
